Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries -January 08, 2024 at 07:31 am EST

Libtayo is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung...

Related Keywords

Brazil ,Canada ,Switzerland ,Medison Pharma ,Inbal Chen ,Gil Gurfinkel ,Meir Jakobsohn ,Prnewswire Medison Pharma ,European Medicines Agency ,Corporate Communications ,Nasdaq ,Regeneron Pharmaceuticals Inc ,European Union ,Regeneron Ireland ,Regeneron Pharmaceuticals ,Executive Chairman ,Approved Indications ,Markets ,